Cancer medications get quick approvals despite little effect on sufferers.

Patients and their doctors should demand that regulators need pharma companies to provide clear proof clinical effectiveness of the drugs, caused by rigorous methodology, suggests Lexchin. Drug agencies just like the Meals and Drug Administration and the European Medicine Agency don't actually look in whether people live longer. Related StoriesSausages With Antioxidants From Berries To Prevent CancerNew antenna-like gadget makes breast cancer surgery easier for surgeonsMeat-rich diet may increase kidney cancers riskIn articles in the British Medical Journal, titled Why do cancer drugs get such an easy ride? , Co-writer and Lexchiin Donald Light, a professor in the institution of Osteopathic Medication, Rowan University in NJ, note that accelerated approval and shortened review situations also make it a steady sail for cancer drugs.Read interesting content about the existing living wage in America at Antiviral therapy may reduce threat of liver cancer in patients with chronic hepatitis B infection One of the most severe complications of hepatitis B may be the development of liver cancer, which is in charge of approximately 745, 000 deaths worldwide each full year. Two new studies appearing in the June issue of Gastroenterology provide solid proof that antiviral therapy can reduce the risk of liver malignancy in individuals with chronic hepatitis B illness. Gastroenterology is the established journal of the American Gastroenterological Association.